GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
February 27, 2024 07:45 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation...
GCANRx Featured in American Journal of Endocannabinoid Medicine
September 21, 2023 08:29 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next...
GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders
July 05, 2023 08:33 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next...
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
October 07, 2022 09:20 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid...
GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special
December 16, 2021 09:35 ET
|
The Greater Cannabis Company, Inc.
The 6th Installment in the Award-winning Series by Dr. Sanjay Gupta will Air on Sunday, December 19th at 9pm ET BALTIMORE, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc....
GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor
December 02, 2021 08:52 ET
|
The Greater Cannabis Company, Inc.
Dr. Aran will be focused on furthering development of the therapeutic pipeline, advancing the clinical study program and supporting IP and regulatory strategies. BALTIMORE, Dec. 02, 2021 (GLOBE...
GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
November 08, 2021 07:50 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid...
GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy
August 19, 2021 09:45 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and...
GCANRx Announces Collaboration with Renowned Cannabis Research Lab
March 16, 2021 09:12 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products...
The Greater Cannabis Company Inc. Announces a Material Reduction in Corporate Debt
June 02, 2020 09:41 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, MD, June 02, 2020 (GLOBE NEWSWIRE) -- (OTCQB:GCAN) - The Greater Cannabis Company, Inc. (the “Company") is pleased to announce that it has eliminated more than US$700,000 of principal and...